The cannabis constituent cannabidiol (CBD) possesses anxiolytic and antipsychotic properties. We have previously shown that transmembrane domain neuregulin 1 mutant (Nrg1 TM HET) mice display altered neurobehavioural responses to the main psychoactive constituent of cannabis, Δ9-tetrahydrocannabinol. Here we investigated whether Nrg1 TM HET mice respond differently to CBD and whether CBD reverses schizophrenia-related phenotypes expressed by these mice. Adult male Nrg1 TM HET and wild type-like littermates (WT) received vehicle or CBD (1, 50 or 100 mg/kg i.p.) for 21 days. During treatment and 48 h after withdrawal we measured behaviour, whole blood CBD concentrations and autoradiographic receptor binding. Nrg1 HET mice displayed locomotor hyperactivity, PPI deficits and reduced 5-HT2A receptor binding density in the substantia nigra, but these phenotypes were not reversed by CBD. However, long-term CBD (50 and 100 mg/kg) selectively enhanced social interaction in Nrg1 TM HET mice. Furthermore, acute CBD (100 mg/kg) selectively increased PPI in Nrg1 TM HET mice, although tolerance to this effect was manifest upon repeated CBD administration. Long-term CBD (50 mg/kg) also selectively increased GABAA receptor binding in the granular retrosplenial cortex in Nrg1 TM HET mice and reduced 5-HT2A binding in the substantia nigra in WT mice. Nrg1 appears necessary for CBD-induced anxiolysis since only WT mice developed decreased anxiety-related behaviour with repeated CBD treatment. Altered pharmacokinetics in mutant mice could not explain our findings since no genotype differences existed in CBD blood concentrations. Here we demonstrate that Nrg1 modulates acute and long-term neurobehavioural effects of CBD, which does not reverse the schizophrenia-relevant phenotypes.
References
[1]
Moore THM, Zammit S, Lingford-Hughes A, Barnes TRE, Jones PB, et al. (2007) Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370: 319–328.
[2]
Frisher M, Crome I, Macleod J, Millson D, Croft P (2005) Substance misuse and psychiatric illness: prospective observational study using the general practice research database. J Epidemiol Community Health 59: 847–850.
[3]
Koethe D, Giuffrida A, Schreiber D, Hellmich M, Schultze-Lutter F, et al. (2009) Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. Br J Psychiatry 194: 371–372.
[4]
Koethe D, Hoyer C, Leweke FM (2009) The endocannabinoid system as a target for modelling psychosis. Psychopharmacology (Berl) 206: 551–561.
[5]
Schwarcz G, Karajgi B, McCarthy R (2009) Synthetic delta-9-tetrahydrocannabinol (dronabinol) can improve the symptoms of schizophrenia. J Clin Psychopharmacol 29: 255–258.
[6]
Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, et al. (2005) Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biological Psychiatry 57: 1117–1127.
[7]
McLaren J, Swift W, Dillon P, Allsop S (2008) Cannabis potency and contamination: a review of the literature. Addiction 103: 1100–1109.
[8]
Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, et al. (2010) Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35: 764–774.
[9]
Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG (1982) Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology 76: 245–250.
[10]
El-Alfy AT, Ivey K, Robinson K, Ahmed S, Radwan M, et al. (2010) Antidepressant-like effect of [Delta]9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. Pharmacology Biochemistry and Behavior 95: 434–442.
[11]
Zanelati TV, Biojone C, Moreira FA, Guimaraes FS, Joca SR (2010) Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. Br J Pharmacol 159: 122–128.
[12]
Campos AC, Guimaraes FS (2008) Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology 199: 223–230.
[13]
Moreira FA, Guimaraes FS (2005) Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. European Journal of Pharmacology 512: 199–205.
[14]
Long LE, Chesworth R, Huang X-F, McGregor IS, Arnold JC, et al. (2010) A behavioural comparison of acute and chronic delta-9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. International Journal of Neuropsychopharmacology 13: 861–876.
[15]
Long LE, Malone DT, Taylor DA (2006) Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice. Neuropsychopharmacology 31: 795–803.
[16]
Moreira FA, Aguiar DC, Guimaraes FS (2006) Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test. Progress in Neuro-Psychopharmacology and Biological Psychiatry 30: 1466–1471.
[17]
Bergamaschi MM, Queiroz RHC, Chagas MHN, de Oliveira DCG, De Martinis BS, et al. (2011) Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology 36: 1219–1226.
[18]
Crippa JA, Zuardi AW, Garrido GE, Wichert-Ana L, Guarnieri R, et al. (2004) Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology 29: 417–426.
[19]
Fusar-Poli P, Crippa JA, Bhattacharyya S, Borgwardt SJ, Allen P, et al. (2009) Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Archives of General Psychiatry 66: 95–105.
[20]
Zuardi AW, Hallak JE, Dursun SM, Morais SL, Faria Sanches R, et al. (2006) Cannabidiol monotherapy for treatment-resistant schizophrenia. Journal of Psychopharmacology 20: 683–686.
[21]
Petitet F, Jeantaud B, Reibaud M, Imperato A, Dubroeucq MC (1998) Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sciences 63: PL1–6.
[22]
Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, et al. (2007) Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 150: 613–623.
[23]
Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, et al. (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152: 1092–1101.
[24]
Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, et al. (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. British Journal of Pharmacology 134: 845–852.
[25]
Karl T, Duffy L, Scimone A, Harvey RP, Schofield PR (2007) Altered motor activity, exploration and anxiety in heterozygous neuregulin 1 mutant mice: implications for understanding schizophrenia. Genes, Brain and Behavior 6: 677–687.
[26]
Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, et al. (2002) Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 71: 877–892.
[27]
O'Tuathaigh CMP, Babovic D, O'Sullivan GJ, Clifford JJ, Tighe O, et al. (2007) Phenotypic characterization of spatial cognition and social behavior in mice with ‘knockout’ of the schizophrenia risk gene neuregulin 1. Neuroscience 147: 18–27.
[28]
Duffy L, Cappas E, Lai D, Boucher A, Karl T (2010) Cognition in transmembrane domain neuregulin 1 mutant mice. Neuroscience 170: 800–807.
[29]
Boucher AA, Arnold JC, Duffy L, Schofield PR, Micheau J, et al. (2007) Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Delta(9)-tetrahydrocannabinol. Psychopharmacology 192: 325–336.
[30]
Boucher AA, Hunt GE, Karl T, Micheau J, McGregor IS, et al. (2007) Heterozygous neuregulin 1 mice display greater baseline and Delta(9)-tetrahydrocannabinol-induced c-Fos expression. Neuroscience 149: 861–870.
[31]
Boucher AA, Hunt GE, Micheau J, Huang X-F, McGregor IS, et al. (2011) The schizophrenia susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids. International Journal of Neuropsychopharmacology 14: 631–643.
[32]
Long LE, Chesworth R, Arnold JC, Karl T (2010) A follow-up study: acute behavioural effects of Δ9-THC in female heterozygous Neuregulin 1 transmembrane domain mutant mice. Psychopharmacology 211: 277–289.
[33]
Powell CM, Miyakawa T (2006) Schizophrenia-relevant behavioral testing in rodent models: a uniquely human disorder? Biological Psychiatry 59: 1198–1207.
[34]
Martin WR, Wikler A, Eades CG, Pescor FT (1963) Tolerance to and Physical Dependence on Morphine in Rats. Psychopharmacologia 4: 247–260.
[35]
O'Tuathaigh CM, O'Connor AM, O'Sullivan GJ, Lai D, Harvey R, et al. (2008) Disruption to social dyadic interactions but not emotional/anxiety-related behaviour in mice with heterozygous ‘knockout’ of the schizophrenia risk gene neuregulin-1. Prog Neuropsychopharmacol Biol Psychiatry 32: 462–466.
[36]
Malone DT, Jongegan D, Taylor DA (2009) Cannabidiol reverses the reduction in social interaction produced by low dose Delta(9)-tetrahydrocannabinol in rats. Pharmacology Biochemistry and Behavior 93: 91–96.
[37]
Klein C, Karanges E, Spiro A, Wong A, Spencer J, et al. (2011) Cannabidiol potentiates Δ9-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats. Psychopharmacology. in press: epub 14/16/11.
[38]
Aubert L, Reiss D, Ouagazzal AM (2006) Auditory and visual prepulse inhibition in mice: parametric analysis and strain comparisons. Genes Brain Behav 5: 423–431.
[39]
Yee BK, Chang DT, Feldon J (2004) The effects of dizocilpine and phencyclidine on prepulse inhibition of the acoustic startle reflex and on prepulse-elicited reactivity in C57BL6 mice. Neuropsychopharmacology 29: 1865–1877.
[40]
Gururajan A, Taylor DA, Malone DT (2011) Effect of cannabidiol in a MK-801-rodent model of aspects of Schizophrenia. Behavioural Brain Research 222: 299–308.
[41]
Karl T, Burne TH, Van den Buuse M, Chesworth R (2011) Do transmembrane domain neuregulin 1 mutant mice exhibit a reliable sensorimotor gating deficit? Behav Brain Res 223: 336–341.
[42]
van den Buuse M, Wischhof L, Xi Lee R, Martin S, Karl T (2009) Neuregulin 1 hypomorphic mutant mice: enhanced baseline locomotor activity but normal psychotropic drug-induced hyperlocomotion and prepulse inhibition regulation. International Journal of Neuropsychopharmacology 12: 1383–1393.
[43]
Deiana S, Watanabe A, Yamasaki Y, Amada N, Arthur M, et al. (2012) Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive–compulsive behaviour. Psychopharmacology 219: 859–873.
[44]
Gunasekaran N, Long LE, Dawson BL, Hansen GH, Richardson DP, et al. (2009) Reintoxication: the release of fat-stored delta-9-tetrahydrocannabinol (THC) into blood is enhanced by food deprivation or ACTH exposure. British Journal of Pharmacology 158: 1330–1337.
[45]
Kreuz DS, Axelrod J (1973) Delta-9-tetrahydrocannabinol: localization in body fat. Science 179: 391–393.
[46]
Porras G, Di Matteo V, Fracasso C, Lucas G, De Deurwaerdere P, et al. (2002) 5-HT2A and 5-HT2C/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum. Neuropsychopharmacology 26: 311–324.
[47]
Schmidt CJ, Fadayel GM, Sullivan CK, Taylor VL (1992) 5-HT2 receptors exert a state-dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine. European Journal of Pharmacology 223: 65–74.
[48]
Dean B, Karl T, Pavey G, Boer S, Duffy L, et al. (2008) Increased levels of serotonin 2A receptors and serotonin transporter in the CNS of neuregulin 1 hypomorphic/mutant mice. Schizophrenia Research 99: 341–349.
[49]
Cato MA, Crosson B, G？k？ay D, Soltysik D, Wierenga C, et al. (2004) Processing words with emotional connotation: an fMRI study of time course and laterality in rostral frontal and retrosplenial cortices. Journal of Cognitive Neuroscience 16: 167–177.
[50]
Keene CS, Bucci DJ (2008) Neurotoxic lesions of retrosplenial cortex disrupt signaled and unsignaled contextual fear conditioning. Behav Neurosci 122: 1070–1077.
[51]
Corbett R, Fielding S, Cornfeldt M, Dunn RW (1991) GABAmimetic agents display anxiolytic-like effects in the social interaction and elevated plus maze procedures. Psychopharmacology 104: 312–316.
[52]
Gomes F, Resstel L, Guimar？es F (2011) The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors. Psychopharmacology 213: 465–473.
[53]
Piomelli D, Tarzia G, Duranti A, Tontini A, Mor M, et al. (2006) Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev 12: 21–38.
[54]
Denenberg VH (1969) Open-field behavior in the rat: what does it mean? Annals of the New York Academy of Sciences 159: 852–859.
[55]
Dere E, Huston JP, De Souza Silva MA (2007) The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents. Neuroscience and Biobehavioral Reviews 31: 673–704.
[56]
Ennaceur A, Delacour J (1988) A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behavioural Brain Research 31: 47–59.
[57]
File SE, Seth P (2003) A review of 25 years of the social interaction test. European Journal of Pharmacology 463: 35–53.
[58]
Ellenbroek BA, Cools AR (2000) Animal models for the negative symptoms of schizophrenia. Behavioural Pharmacology 11: 223–233.
[59]
Braff DL, Geyer MA, Swerdlow NR (2001) Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology 156: 234–258.
[60]
Geyer MA, Dulawa SC (2003) Assessment of murine startle reactivity, prepulse inhibition, and habituation. Curr Protoc Neurosci Chapter 8: Unit 8 17.
[61]
Karschner E, Barnes A, Lowe R, Scheidweiler K, Huestis M (2010) Validation of a two-dimensional gas chromatography mass spectrometry method for the simultaneous quantification of cannabidiol, Δ9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC in plasma. Analytical and Bioanalytical Chemistry 397: 603–611.
[62]
Nadulski T, Sporkert F, Schnelle M, Stadelmann AM, Roser P, et al. (2005) Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract. Journal of Analytical Toxicology 29: 782–789.
[63]
Deng C, Han M, Huang XF (2007) No changes in densities of cannabinoid receptors in the superior temporal gyrus in schizophrenia. Neuroscience Bulletin 23: 341–347.
[64]
Han M, Huang XF, du Bois TM, Deng C (2009) The effects of antipsychotic drugs administration on 5-HT1A receptor expression in the limbic system of the rat brain. Neuroscience 164: 1754–1763.
[65]
Kang K, Huang X-F, Wang Q, Deng C (2009) Decreased density of serotonin 2A receptors in the superior temporal gyrus in schizophrenia-a postmortem study. Progress in Neuro-Psychopharmacology and Biological Psychiatry 33: 867–871.
[66]
Newell KA, Zavitsanou K, Huang XF (2007) Short and long term changes in NMDA receptor binding in mouse brain following chronic phencyclidine treatment. Journal of Neural Transmission 114: 995–1001.
[67]
Deng C, Huang X-F (2006) Increased density of GABAA receptors in the superior temporal gyrus in schizophrenia. Experimental Brain Research 168: 587–590.
[68]
Paxinos G, Franklin KBJ (2004) The mouse brain in stereotaxic coordinates: Oxford Academic.
